MX2011012541A - Compuestos heterociclicos antivirales. - Google Patents

Compuestos heterociclicos antivirales.

Info

Publication number
MX2011012541A
MX2011012541A MX2011012541A MX2011012541A MX2011012541A MX 2011012541 A MX2011012541 A MX 2011012541A MX 2011012541 A MX2011012541 A MX 2011012541A MX 2011012541 A MX2011012541 A MX 2011012541A MX 2011012541 A MX2011012541 A MX 2011012541A
Authority
MX
Mexico
Prior art keywords
antiviral compound
heterocyclic antiviral
heterocyclic
hepatitis
compositions
Prior art date
Application number
MX2011012541A
Other languages
English (en)
Inventor
Elbert Chin
Jim Li
Alfred Sui-Ting Lui
Francisco Xavier Talamas
Vicente Fidalgo Javier De
Kristen Lynn Mccaleb
Ryan Craig Schoenfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011012541A publication Critical patent/MX2011012541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos que tienen la fórmula I, en la que R1, R2, R3, R4, y R5 tienen los significados aquí definidos, son inhibidores de la polimerasa NS5B del virus de la hepatitis C. Se describen también composiciones y métodos para tratar una infección del HCV y para inhibir la replicación del HCV.
MX2011012541A 2009-06-24 2010-06-21 Compuestos heterociclicos antivirales. MX2011012541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21997709P 2009-06-24 2009-06-24
PCT/EP2010/058681 WO2010149598A2 (en) 2009-06-24 2010-06-21 Heterocyclic antiviral compound

Publications (1)

Publication Number Publication Date
MX2011012541A true MX2011012541A (es) 2012-08-03

Family

ID=42942262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012541A MX2011012541A (es) 2009-06-24 2010-06-21 Compuestos heterociclicos antivirales.

Country Status (13)

Country Link
US (1) US8158631B2 (es)
EP (1) EP2445875A2 (es)
JP (1) JP2012530751A (es)
CN (1) CN102803212A (es)
AR (1) AR077173A1 (es)
AU (1) AU2010264802A1 (es)
BR (1) BRPI1011744A2 (es)
CA (1) CA2762675A1 (es)
IL (1) IL216338A0 (es)
MX (1) MX2011012541A (es)
SG (1) SG176976A1 (es)
TW (1) TW201103545A (es)
WO (1) WO2010149598A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178547B2 (en) * 2008-12-22 2012-05-15 Roche Palo Alto Llc Heterocyclic antiviral compounds
EP2411352B1 (en) * 2009-03-25 2017-01-18 AbbVie Inc. Antiviral compounds and uses thereof
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
JP6030057B2 (ja) 2010-07-16 2016-11-24 アッヴィ・バハマズ・リミテッド 触媒反応用ホスフィンリガンド
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
KR101893751B1 (ko) 2010-07-16 2018-09-03 애브비 아일랜드 언리미티드 컴퍼니 항바이러스성 화합물의 제조 방법
CA2882624A1 (en) * 2012-08-21 2014-02-27 Shashank Shekhar Process for preparing antiviral compounds
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1407899A (en) * 1997-12-01 1999-06-16 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19932813A1 (de) * 1999-07-14 2001-01-18 Bayer Ag Substituierte Phenyluracile
DE60034027T2 (de) 1999-12-24 2007-12-13 Asahi Glass Co., Ltd. Siliziumnitridfilter und verfahren zu dessen herstellung
JP2004509066A (ja) 2000-05-10 2004-03-25 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
WO2003059356A2 (en) 2001-10-30 2003-07-24 Smithkline Beecham Corporation Novel anti-infectives
AU2003248566A1 (en) 2002-05-24 2003-12-12 Smithkline Beecham Corporation Novel anti-infectives
MXPA05004670A (es) 2002-11-01 2005-08-18 Abbott Lab Agentes anti-infecciones.
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
AU2003300956A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
AU2003300957A1 (en) 2002-12-11 2004-06-30 Smithkline Beecham Corporation Anti-infectives
WO2004058150A2 (en) 2002-12-17 2004-07-15 Smithkline Beecham Corporation Anti-infectives
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
EP1786807B1 (en) 2004-08-23 2009-07-29 F.Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2607089A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
JP5258889B2 (ja) 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
TW200924751A (en) 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
AU2008295483B2 (en) 2007-08-29 2013-11-21 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and their use for treating or preventing viral infections
PA8796201A1 (es) * 2007-09-17 2009-04-23 Abbott Lab Agentes anti-infecciosos y su uso
JP5726527B2 (ja) * 2007-09-17 2015-06-03 アッヴィ・バハマズ・リミテッド Ｃ型肝炎ウイルス（ｈｃｖ）阻害薬として有用なｎ−フェニル−ジオキソ−ヒドロピリミジン
EP2368882B1 (en) 2007-09-17 2014-08-13 AbbVie Bahamas Ltd. Anti-infective pyrimidines and uses thereof
CA2705586A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
EP2411352B1 (en) 2009-03-25 2017-01-18 AbbVie Inc. Antiviral compounds and uses thereof
MX2011010047A (es) 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.

Also Published As

Publication number Publication date
JP2012530751A (ja) 2012-12-06
BRPI1011744A2 (pt) 2016-03-22
TW201103545A (en) 2011-02-01
AR077173A1 (es) 2011-08-10
IL216338A0 (en) 2012-01-31
US20100330032A1 (en) 2010-12-30
EP2445875A2 (en) 2012-05-02
WO2010149598A3 (en) 2011-05-19
WO2010149598A2 (en) 2010-12-29
CN102803212A (zh) 2012-11-28
CA2762675A1 (en) 2010-12-29
SG176976A1 (en) 2012-02-28
AU2010264802A1 (en) 2012-01-19
US8158631B2 (en) 2012-04-17

Similar Documents

Publication Publication Date Title
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
MY157435A (en) Heterocyclic antiviral compounds
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
TW200745151A (en) Antiviral nucleosides
TW200720285A (en) Nucleoside compounds for treating viral infections
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2011012541A (es) Compuestos heterociclicos antivirales.
HK1128131A1 (en) Hepatitis c virus inhibitors
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MX2012006513A (es) Compuestos heterociclicos antivirales.
TW200724540A (en) Heterocyclic antiviral compounds
WO2009069095A3 (en) Antiviral nucleoside compounds
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
MX2011011112A (es) Compuestos antivirales heterociclicos.
SI2209789T1 (sl) Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
MX2011008641A (es) Compuestos heterociclicos antivirales.
WO2012019299A9 (en) Hepatitis c inhibitor compounds
MX2011012240A (es) Compuestos heterociclicos antivirales.
TW201129362A (en) Heterocyclic antiviral compounds
BR112013000245A2 (pt) compostos antivirais heterocíclicos
MX2012002958A (es) Compuestos antivirales heterociclicos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal